Ambry becomes one of the first to offer full sequencing of the cystic fibrosis gene, CFTR, on a commercial basis. This helps diagnose many with the condition, putting Ambry on the map and linking the company with the patient community. Ambry goes on to responsibly be first-to-market for numerous other tests, and this continues today.
Charles Dunlop and his brother, James, read an article in The New England Journal of Medicine that offers scientific support for ocean water as a natural therapy for those with cystic fibrosis. Both lifelong surfers, Charles and James are inspired to create the Mauli Ola Foundation. This non-for-profit foundation supports those with cystic fibrosis and other inherited conditions by getting them in or near the ocean with professional surfers.
Ambry is amongst the first to offer next generation sequencing (NGS) technology with an 81-gene test for X-linked intellectual disability. NGS becomes a solid backbone for many future diagnostic options for Ambry.
Ambry galvanizes its scientific skill, experience, and entrepreneurial spirit to be the first to offer whole exome sequencing on a clinical basis. Clinicians respond well and find long-awaited diagnostic answers for their patients on a continual basis.
Ambry stays committed to ending data hoarding and securely sharing its data with the scientific community to further understanding. It bravely takes a stand on gene patenting legislation, and also becomes the first to offer BRCA1/2 gene testing after the U.S. Supreme Court rules on this issue.
Continuing with its goal to unlock data, Ambry announces AmbryShare. Ambry has collected anonymous exome sequencing data and family health information from over 11,400 people. It now opens registration to the public, to share all data freely with groups that have the promise to increase collective understanding.